These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7418343)

  • 1. Chemotherapy of metastatic carcinoma of the breast.
    Hancock B; Todd ID; Wilkinson PM
    Clin Radiol; 1980 Jul; 31(4):433-6. PubMed ID: 7418343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemotherapy in metastatic breast cancer].
    Kuten A; Lev L; Mohaliver J; Robinson E
    Harefuah; 1981 Feb; 100(3):118-20. PubMed ID: 7262675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
    Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
    Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
    Hirshaut Y; Kesselheim H
    Cancer; 1983 Jun; 51(11):1998-2004. PubMed ID: 6687698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.
    Abeloff MD; Ettinger DS
    Cancer Treat Rep; 1977 Dec; 61(9):1685-9. PubMed ID: 340033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.
    Irwin LE; Chlebowski RT; Weiner JM; Reynolds R; Pugh RP; Ryden VM; Bateman JR
    Cancer Treat Rep; 1980; 64(8-9):981-4. PubMed ID: 7004635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
    Ruffert K
    Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four hour combination chemotherapy: a feasibility study with implications for improved adjuvant treatment of breast cancer.
    Price LA; Hill BT; Marks P; Howell A; Monypenny I; Morrison JM
    Eur J Cancer Clin Oncol; 1983 Jan; 19(1):1-4. PubMed ID: 6682768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Colozza M; Tonato M; Grignani F; Davis S
    Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
    Henderson IC; Gelman R; Canellos GP; Frei E
    Cancer Treat Rep; 1981; 65 Suppl 1():67-75. PubMed ID: 6976832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
    Herr HW
    J Urol; 1982 Mar; 127(3):462-5. PubMed ID: 7062419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate.
    White DR; Richards F; Muss HB; Cooper MR; Spurr CL
    Cancer; 1980 Feb; 45(4):662-5. PubMed ID: 6986968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy of advanced breast cancer--actual results ].
    Matthes ML; Lenk H; Gürtler R; Tanneberger S
    Arch Geschwulstforsch; 1982 May; 52(3):241-6. PubMed ID: 6812538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.